報價延遲最少15分鐘:2026/01/09 23:17 EST
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
16.23 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-3.00/-3.57
|
|
企業價值
1.44B
|
| 資產負債 |
|
每股賬面淨值
2.42
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
43.27M
|
|
每股收益
0.51
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| EyePoint Inc focuses on developing and commercializing innovative therapeutics for serious retinal diseases. It develops therapies for serious retinal diseases to provide durable treatments that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained release product candidate for retinal diseases with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD. |
